PT4327866T - Mirikizumab no tratamento da colite ulcerosa - Google Patents

Mirikizumab no tratamento da colite ulcerosa

Info

Publication number
PT4327866T
PT4327866T PT232156265T PT23215626T PT4327866T PT 4327866 T PT4327866 T PT 4327866T PT 232156265 T PT232156265 T PT 232156265T PT 23215626 T PT23215626 T PT 23215626T PT 4327866 T PT4327866 T PT 4327866T
Authority
PT
Portugal
Prior art keywords
mirikizumab
treatment
ulcerous colitis
ulcerous
colitis
Prior art date
Application number
PT232156265T
Other languages
English (en)
Portuguese (pt)
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of PT4327866T publication Critical patent/PT4327866T/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244Interleukins [IL]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
PT232156265T 2018-03-30 2019-03-28 Mirikizumab no tratamento da colite ulcerosa PT4327866T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862650314P 2018-03-30 2018-03-30

Publications (1)

Publication Number Publication Date
PT4327866T true PT4327866T (pt) 2026-02-17

Family

ID=66429483

Family Applications (2)

Application Number Title Priority Date Filing Date
PT232156265T PT4327866T (pt) 2018-03-30 2019-03-28 Mirikizumab no tratamento da colite ulcerosa
PT197222565T PT3773715T (pt) 2018-03-30 2019-03-28 Miricizumab no tratamento da colite ulcerosa

Family Applications After (1)

Application Number Title Priority Date Filing Date
PT197222565T PT3773715T (pt) 2018-03-30 2019-03-28 Miricizumab no tratamento da colite ulcerosa

Country Status (29)

Country Link
US (2) US12152072B2 (https=)
EP (2) EP4327866B1 (https=)
JP (4) JP7119114B2 (https=)
KR (1) KR102552693B1 (https=)
CN (1) CN111936165A (https=)
AU (2) AU2019243283C1 (https=)
BR (1) BR112020018099A2 (https=)
CA (1) CA3095297A1 (https=)
DK (2) DK3773715T3 (https=)
EA (1) EA202091989A1 (https=)
ES (2) ES3063700T3 (https=)
FI (2) FI4327866T3 (https=)
HR (2) HRP20260275T1 (https=)
HU (1) HUE067445T2 (https=)
IL (2) IL277514B2 (https=)
LT (2) LT3773715T (https=)
MA (2) MA52216B1 (https=)
MD (2) MD4327866T2 (https=)
MX (1) MX2020010269A (https=)
MY (1) MY202368A (https=)
PL (2) PL4327866T3 (https=)
PT (2) PT4327866T (https=)
RS (2) RS67806B1 (https=)
SG (1) SG11202009526RA (https=)
SI (2) SI3773715T1 (https=)
TW (2) TWI744617B (https=)
UA (1) UA128578C2 (https=)
WO (1) WO2019191464A1 (https=)
ZA (1) ZA202005388B (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7805788B2 (ja) 2019-05-23 2026-01-26 ヤンセン バイオテツク,インコーポレーテツド Il-23及びtnfアルファに対する抗体の併用療法による炎症性腸疾患の治療方法
BR112022015996A2 (pt) * 2020-02-14 2022-10-11 Janssen Biotech Inc Método seguro e eficaz para tratar colite ulcerativa com anticorpo anti-il12/il23
IL298389A (en) 2020-05-21 2023-01-01 Janssen Biotech Inc Method of treating inflammatory bowel disease with a combination therapy of antibodies to il-23 and tnf alpha
JP7423815B2 (ja) * 2020-10-20 2024-01-29 セトラスホールディングス株式会社 治験管理装置、治験管理方法、治験管理プログラム及び治験管理システム
TW202241506A (zh) * 2021-01-06 2022-11-01 美商艾伯維有限公司 治療克羅恩氏病及潰瘍性結腸炎之方法
BR112023024064A2 (pt) * 2021-05-20 2024-01-30 Janssen Biotech Inc Método de tratamento de doença inflamatória intestinal com uma terapia de combinação de anticorpos para il-23 e tnf-alfa
JP2024521748A (ja) * 2021-05-28 2024-06-04 イーライ リリー アンド カンパニー 潰瘍性大腸炎に関与する遺伝子の抗il-23p19抗体調節
US20230159633A1 (en) * 2021-11-23 2023-05-25 Janssen Biotech, Inc. Method of Treating Ulcerative Colitis with Anti-IL23 Specific Antibody
AU2023383916A1 (en) * 2022-11-22 2025-07-10 Janssen Biotech, Inc. Method of treating ulcerative colitis with anti-il23 specific antibody
TW202500184A (zh) 2023-03-10 2025-01-01 美商美國禮來大藥廠 治療潰瘍性結腸炎之方法
CN121443635A (zh) * 2023-06-16 2026-01-30 信达生物医药科技(杭州)有限公司 重组抗白介素23p19亚基抗体在治疗炎症性肠病中的用途
WO2025170982A2 (en) 2024-02-06 2025-08-14 Paragon Therapeutics, Inc. Il-23 antibody compositions and methods of use
WO2026060205A1 (en) 2024-09-13 2026-03-19 Eli Lilly And Company PAN-ELR+ CXC CHEMOKINE ANTIBODIES AND IL-23p19 ANTIBODIES FOR THE TREATMENT OF ULCERATIVE COLITIS

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2452694T1 (sl) * 2005-06-30 2019-05-31 Janssen Biotech, Inc. Protitelesa proti-IL-23, sestavki in postopki uporabe
HUE034269T2 (en) 2005-12-29 2018-02-28 Janssen Biotech Inc Human anti-IL-23 antibodies, preparations, methods and applications
ES2708988T3 (es) 2007-02-23 2019-04-12 Merck Sharp & Dohme Anticuerpos anti-IL-23p19 obtenidos por ingeniería genética
JP2012507723A (ja) * 2008-11-03 2012-03-29 シェーリング コーポレイション 炎症性腸疾患生物マーカーおよび関連治療方法
JO3244B1 (ar) 2009-10-26 2018-03-08 Amgen Inc بروتينات ربط مستضادات il – 23 البشرية
MX2019000046A (es) * 2010-11-04 2023-10-05 Boehringer Ingelheim Int Anticuerpos anti-il-23.
AR094877A1 (es) 2013-03-08 2015-09-02 Lilly Co Eli Anticuerpos que se unen a il-23
US20170002060A1 (en) * 2014-01-08 2017-01-05 Moderna Therapeutics, Inc. Polynucleotides for the in vivo production of antibodies
MX2020009265A (es) * 2018-03-05 2020-10-01 Janssen Biotech Inc Metodos para tratar la enfermedad de crohn con un anticuerpo especifico anti-il23.

Also Published As

Publication number Publication date
SI4327866T1 (sl) 2026-04-30
MA52216A (fr) 2021-02-17
MX2020010269A (es) 2020-11-06
RS67806B1 (sr) 2026-03-31
PT3773715T (pt) 2024-05-27
LT4327866T (lt) 2026-03-10
WO2019191464A1 (en) 2019-10-03
US12152072B2 (en) 2024-11-26
AU2023248103B2 (en) 2026-02-05
HRP20240904T1 (hr) 2024-10-11
ES2983809T3 (es) 2024-10-24
TWI744617B (zh) 2021-11-01
CA3095297A1 (en) 2019-10-03
HRP20260275T1 (hr) 2026-04-10
DK4327866T3 (da) 2026-02-23
ES3063700T3 (en) 2026-04-20
NZ767902A (en) 2024-05-31
IL277514B2 (en) 2024-11-01
MY202368A (en) 2024-04-24
JP2025020134A (ja) 2025-02-12
SI3773715T1 (sl) 2024-06-28
JP2022169562A (ja) 2022-11-09
ZA202005388B (en) 2025-05-28
MD3773715T2 (ro) 2024-10-31
EA202091989A1 (ru) 2021-01-13
US20250034243A1 (en) 2025-01-30
LT3773715T (lt) 2024-06-25
FI3773715T3 (fi) 2024-05-30
SG11202009526RA (en) 2020-10-29
MA52216B1 (fr) 2024-07-31
MD4327866T2 (ro) 2026-04-30
PL3773715T3 (pl) 2024-08-19
JP7331219B2 (ja) 2023-08-22
US20210032325A1 (en) 2021-02-04
AU2023248103A1 (en) 2023-11-09
BR112020018099A2 (pt) 2020-12-22
IL312807B1 (en) 2025-02-01
PL4327866T3 (pl) 2026-04-20
TW201946657A (zh) 2019-12-16
TW202206104A (zh) 2022-02-16
EP4327866A2 (en) 2024-02-28
EP4327866B1 (en) 2025-12-10
JP2023166388A (ja) 2023-11-21
JP2021517156A (ja) 2021-07-15
IL312807A (en) 2024-07-01
DK3773715T3 (da) 2024-05-27
MA67901B1 (fr) 2026-02-27
RS65661B1 (sr) 2024-07-31
IL277514B1 (en) 2024-07-01
UA128578C2 (uk) 2024-08-21
KR102552693B1 (ko) 2023-07-07
EP3773715A1 (en) 2021-02-17
AU2019243283B2 (en) 2023-07-27
HUE067445T2 (hu) 2024-10-28
AU2019243283A1 (en) 2020-09-24
JP7571225B2 (ja) 2024-10-22
IL312807B2 (en) 2025-06-01
FI4327866T3 (fi) 2026-02-18
JP7119114B2 (ja) 2022-08-16
IL277514A (en) 2020-11-30
TWI837532B (zh) 2024-04-01
EP3773715B1 (en) 2024-05-08
EP4327866A3 (en) 2024-03-20
CN111936165A (zh) 2020-11-13
KR20200128101A (ko) 2020-11-11
AU2019243283C1 (en) 2024-05-02

Similar Documents

Publication Publication Date Title
PT4327866T (pt) Mirikizumab no tratamento da colite ulcerosa
IL289975A (en) Use of cannabidiol in the treatment of dravet syndrome
IL283086A (en) Use of cannabidiol in the treatment of tuberous sclerosis complex
DK3641819T3 (da) Anvendelse af cannabidiol i behandling af tuberøst sklerosekompleks
HUE054548T2 (hu) Amino-triazolopiridin vegyületek és azok alkalmazása rák kezelésében
DK3347030T3 (da) Brug af pasteuriseret akkermansia til behandling af stofskiftesygdomme
DK3578547T3 (da) Sulfonylureaer og relaterede forbindelser og brug af samme
DK3704108T3 (da) Irak4-hæmmer i kombination med en bcl-2-hæmmer til anvendelse i cancerbehandling
EP3710095C0 (en) FRICTIONLESS CATHETER
IL258259A (en) Adjunctive therapy with 25-hydroxyvitamin d and articles therefor
IL260771B1 (en) Catheter locking solution and catheter locking therapy
IL271863B (en) Compounds and use thereof for the treatment of microbial infections
EP3858943A4 (en) Surface treatment agent
IL272200A (en) Isochroman compounds and uses thereof
DK3576738T3 (da) Gaboxadolmonohydrat i behandling af tinnitus
DK3710000T3 (da) Tradipitant til anvendelse til behandling af gastroparese
HUE058314T2 (hu) Pridopidin alkalmazása Rett-szindróma kezelésére
IL287704A (en) Use of cannabidiol in the treatment of tuberous sclerosis complex
PL3592355T3 (pl) Kx2-391/kx-01 do zastosowania w leczeniu rogowacenia słonecznego
DK3706739T3 (da) Anvendelse af riluzolprodrugs til behandling af ataksier
DK3125874T3 (da) Et terapeutisk middel til anvendelse i behandlingen af infektioner
IL289371A (en) Methylthioninium for use in the treatment of synaptopathies
CY2024037I2 (el) Χρηση delgocitinib για την θεραπεια χρονιουεκζεματος χεριων
EP3903872A4 (en) BENDABLE CATHETER
DK3157532T3 (da) Fremgangsmåder til behandling og forebyggelse af sygdomme med vaskulær instabilitet